Drug Details
General Information of the Drug (ID: DR1258) | ||||
---|---|---|---|---|
Name |
Methotrexate
|
|||
Synonyms |
diazinon; Dimpylate; 333-41-5; Diazinone; Oleodiazinon; Neocidol; Spectracide; Diazitol; Nedcidol; Dassitox; Ciazinon; Ektoband; Nucidol; Flytrol; Exodin; Galesan; Bazuden; Diazol; Diazide; Sarolex; Dazzel; Dacutox; Basudin; Antigal; Dicid; Alfa-tox; Diazajet; Dimpylat; Garden Tox; Neocidol (oil); Bassadinon; Terminator; Kayazol; Dizinon; Disonex; Compass; Meodinon; Kayazinon; Drawizon; Nipsan; Dyzol; Diazinon ag 500; Knox-out; Neodinon; Optimizer; Dimpylatum; Delzinon; Dizictol; Dipofene; Dizinil; Bazudin; Srolex; Basudin 10 G; Geigy 24480; Basudin S; Knox
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Leukaemia [ICD-11: 2A60-2B33] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C20H22N8O5
|
|||
PubChem CID | ||||
Canonical SMILES |
CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
|
|||
InChI |
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
|
|||
InChIKey |
FBOZXECLQNJBKD-ZDUSSCGKSA-N
|
|||
CAS Number |
CAS 59-05-2
|
|||
GDSC | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
17-beta-Estradiol | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MDA-MB-436 | CVCL_0623 | Invasive breast carcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
Experimental
Result(s) |
17-beta-oestradiol partially reversed the anti-proliferative effects of MTX in the MDA-MB-436 line and potentiated growth inhibition in the E2 responsive cells. | |||||
Acitretin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | Male K14-VEGF mice (10 weeks old) were used in this study. | |||||
Experimental
Result(s) |
The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. | |||||
Astilbin | Smilax glabra | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | STAT1 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Specific-pathogen-free, eight-week-old male DBA/1J mice, and Eight-week-old C57BL/6 mice were used in this study. | |||||
Experimental
Result(s) |
Astilbin is a valuable candidate for low-dose MTX combined therapy in RA via increasing A2AAR/adenosine system and decreasing ERK/NFKappaB/STATs signals. | |||||
Bucillamine | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | Clinical Trial | |||||
Experimental
Result(s) |
The triple DMARD combination therapy provided a new treatment option for those patients for whom treatment with biologics is difficult. | |||||
Glycyrrhizin | Glycyrrhiza glabra | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Experimental
Result(s) |
Methotrexate and compound glycyrrhizin can be an effective alternative therapy in the treatment of erythrodermic psoriasis with BP. | |||||
Green tea catechins | Theaceae | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Pseudomonas aeruginosa | Microorganism model | Pseudomonas aeruginosa | |||
Staphylococcus aureus | Microorganism model | Staphylococcus aureus | ||||
Experimental
Result(s) |
Green tea extract and catechins potentiated the antimicrobial action of gentamicin against some clinical isolates of S. aureus and standard P. aeruginosa strains. | |||||
Silibinin | Carduus marianus | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | Human rhabdomyosarcoma | Rhabdomyosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines. | |||||
Sinomenine | Sinomenium | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Arthritis was induced by immunizing with CII in female Srague-Dawley rats. | |||||
Experimental
Result(s) |
SIN and MTX have additive effects, decreasing inflammation and joint damage in CIA rats by modulating osteoclast-related cytokines. These results are indicative of the combined effect of SIN and MTX for anti-arthritic treatment in RA. | |||||
Vinblastine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Experimental
Result(s) |
Low-dose chemotherapy with methotrexate and vinblastine for 1 year was effective and well tolerated by adult patients with aggressive, recurrent fibromatosis. | |||||
Vincristine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | MOLT-3 | CVCL_0624 | Adult T acute lymphoblastic leukemia | Homo sapiens | ||
Experimental
Result(s) |
Simultaneous exposure of VCR and MTX produced subadditive or mutually protective interactions. | |||||
β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
Chlorogenic acid | Imperata cylindrica | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | LDHA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Attennuation | Pro-inflammatory and apoptotic mediators | ||||
Improvement | Antioxidant competence | |||||
In-vivo Model | 6-8 weeks old Male Wistar rats (150-200 g) were use in this study. | |||||
Experimental
Result(s) |
CGA has perfective effect against MTX-induced liver injury. | |||||
Gentiopicroside | Gentiana | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
In-vivo Model | SD rats (200 g +/- 20 g) were used in this study. | |||||
Experimental
Result(s) |
Gentiopicroside (GPS) could exert hepatoprotective effects on leflunomide (LEF)- and/or methotrexate (MTX)-treated arthritic rats. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Proton-coupled folate transporter (SLC46A1) | Molecule Info | [14] | |
Reduced folate carrier protein (SLC19A1) | Molecule Info | [15] |